01Novo Nordisk is scheduled to report Q2 2026 earnings on August 14, 2026 after market close, with analysts expecting EPS of $0.81 and revenue of $11.3B.
02The stock trades at $46.75 with a market capitalization of $223.5B, and revenue is expected to increase from the prior year quarter.
03Recent earnings history shows volatility, with Q2 2026 actual EPS of $0.96 beating the $0.81 estimate by 18.6%, while Q1 2026 reported a loss of $0.00 against an $0.87 estimate.
Earnings Results
Novo Nordisk A/S (NYSE:NVO) is scheduled to report its Q2 earnings results on August 14, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $0.81, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $11.3B, up from a year ago.
Company Overview
The stock currently trades at $46.75 with a market capitalization of $223.5B.
Ahead of Novo Nordisk A/S's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Novo Nordisk A/S should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.